US Drug Recall Register
Class II · Moderate risk Terminated Initiated Dec 22, 2022 (4 years ago)

Tacrolimus 0.03% Oph Solution Tacrolimus 0.1%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

What was recalled

TACROLIMUS 0.03% OPH SOLUTION TACROLIMUS 0.1% (1ML DROPTAINER) OPH SOLUTION TACROLIMUS -CORN OIL- 0.03% OPH SOLUTION TACROLIMUS-VET- 0.02% (10ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (15ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.02% (5ML DROPPER) OPHTHALMIC TACROLIMUS-VET- 0.03% (10ML DROPPER) OPHTHALMIC, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Recalling firm
Pharmacy Innovations
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0237-2023

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Tacrolimus recalls

See all
Class I · High risk Ongoing

Prograf

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk Ongoing

Astagraf XL

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk Terminated

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk Ongoing

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023
Class III · Low risk Ongoing

Tacrolimus Ointment

Reason Defective Container: Tube split from side seam

Glenmark Pharmaceuticals Inc., USA NDC 68462-534-35 D-1304-2022